Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01832441

Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus. (BMACD)

Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus. It is Self Funded (Patients' Own Funding) Clinical Trial

Sponsor: Chaitanya Hospital, Pune

Conditions Diabetes Mellitus.

Interventions Intra thecal transplantation of autologous MNC

Updated 5 times since 2017 Last updated: Sep 16, 2014 Started: Sep 30, 2014 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01832441, this PHASE1/PHASE2 trial focuses on Diabetes Mellitus. and remains ongoing. Sponsored by Chaitanya Hospital, Pune, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chaitanya Hospital, Pune

Data source: Chaitanya Hospital, Pune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pune, India